Home » Stocks » CERS

Cerus Corporation (CERS)

Stock Price: $6.72 USD -0.05 (-0.74%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Pre-market: $6.90 +0.18 (2.68%) Feb 25, 7:35 AM
Market Cap 1.12B
Revenue (ttm) 107.15M
Net Income (ttm) -62.40M
Shares Out 166.57M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $6.72
Previous Close $6.77
Change ($) -0.05
Change (%) -0.74%
Day's Open 6.71
Day's Range 6.50 - 6.93
Day's Volume 1,461,151
52-Week Range 2.71 - 8.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guida...

Seeking Alpha - 2 months ago

Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021...

Business Wire - 2 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with t...

Business Wire - 2 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for...

Zacks Investment Research - 2 months ago

Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Business Wire - 2 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryopre...

Zacks Investment Research - 3 months ago

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Business Wire - 3 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief f...

Seeking Alpha - 3 months ago

Cerus Corporation (CERS) CEO Obi Greenman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 2.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include:...

Zacks Investment Research - 4 months ago

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close ...

Seeking Alpha - 4 months ago

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: GOSS
Business Wire - 4 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of ne...

Business Wire - 4 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October...

InvestorPlace - 5 months ago

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: ADMA, AZN, BNTX, LMNL, PFE, SONN
Zacks Investment Research - 6 months ago

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: KMDA, TTOO
Benzinga - 6 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, GRFS, KMDA, LMNL, SONN, THMO, TTOO
Business Wire - 6 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma...

Seeking Alpha - 6 months ago

Cerus Corporation (CERS) CEO Obi Greenman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020.

Business Wire - 6 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCE...

Business Wire - 7 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of...

Business Wire - 7 months ago

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for CO...

Zacks Investment Research - 8 months ago

Is (CERS) Outperforming Other Medical Stocks This Year?

CNBC Television - 8 months ago

Cerus CEO on convalescent plasma, blood centers being the pandemic's 'unsung heroes'

Biotech company Cerus CEO Obi Greenman discussed early findings of using plasma to fight Covid-19.

Zacks Investment Research - 8 months ago

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 9 months ago

Cerus: Surging During The COVID-19 Pandemic

Seeking Alpha - 9 months ago

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 9 months ago

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Cerus Corporation (CERS).

Seeking Alpha - 11 months ago

Cerus: Looks Ready To Breakout Following Another Positive Earnings Report

Seeking Alpha - 1 year ago

Cerus Corporation (CERS) CEO Obi Greenman on Q4 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

Other stocks mentioned: AHPI, APT, BCRX, CODX, DYAI, INO, LAKE, MRNA, NNVC, NVAX, VIR
24/7 Wall Street - 1 year ago

The newest coronavirus out of China has resulted in a rising interest in biotechs that may be able to produce a vaccine or treatment with a short turnaround.

Benzinga - 1 year ago

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

Other stocks mentioned: AEMD, APT, AZN, BCRX, CBLI, CODX, INO, LAKE, MRNA, NNVC, NVAX, VIR
Seeking Alpha - 1 year ago

Cerus: Prepared For A Watershed Event

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: NEPH, NOG, SYRS, ZNGA
Seeking Alpha - 1 year ago

Cerus Corporation's (CERS) CEO Obi Greenman on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

The company recently reported their Q2 earnings revealing increased demand for their INTERCEPT products with a slight beat on revenue and a slight miss on EPS.

Seeking Alpha - 1 year ago

Cerus Corporation (CERS) CEO Obi Greenman on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2019 Results - Earnings Call Transcript

About CERS

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 1997
CEO
William Greenman
Employees
254
Stock Exchange
NASDAQ
Ticker Symbol
CERS
Full Company Profile

Financial Performance

In 2019, Cerus's revenue was $93.77 million, an increase of 23.30% compared to the previous year's $76.05 million. Losses were -$71.24 million, 23.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Cerus stock is "Strong Buy." The 12-month stock price forecast is 9.30, which is an increase of 38.39% from the latest price.

Price Target
$9.30
(38.39% upside)
Analyst Consensus: Strong Buy